Upon failure of first-line ADT, should second-line hormonal manipulation without survival benefit data still be used?
暂无分享,去创建一个
[1] I. Tannock,et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] I. Tannock,et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] D. Dearnaley,et al. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. , 2015, European urology.
[4] F. Saad,et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). , 2014, European urology.
[5] F. Saad,et al. 753OFINAL OVERALL SURVIVAL (OS) ANALYSIS OF COU-AA-302, A RANDOMIZED PHASE 3 STUDY OF ABIRATERONE ACETATE (AA) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) WITHOUT PRIOR CHEMOTHERAPY. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] D. Dearnaley,et al. 764PDA RANDOMISED PHASE II TRIAL OF DEXAMETHASONE VERSUS PREDNISOLONE IN CASTRATION RESISTANT PROSTATE CANCER. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] K. Kihara,et al. Prostate‐specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration‐resistant prostate cancer , 2012, BJU international.
[8] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[9] C. Tangen,et al. Antiandrogen withdrawal in castrate‐refractory prostate cancer , 2008, Cancer.
[10] L. Ngo,et al. Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore. , 2007, Annals of the Academy of Medicine, Singapore.
[11] R. Jennrich,et al. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. , 2005, The Journal of urology.
[12] K. Akakura,et al. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. , 2004, The Journal of urology.
[13] W. Kassouf,et al. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. , 2003, The Journal of urology.
[14] W. Stadler,et al. Nilutamide: possible utility as a second-line hormonal agent. , 2001, Urology.
[15] C. Moinpour,et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). , 2001, Urology.
[16] L. Schwartz,et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] N. Bissada,et al. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. , 1995, The Journal of urology.
[18] W. Lowrance,et al. Castration-resistant prostate cancer: AUA guideline amendment. , 2015, The Journal of urology.
[19] Thomas Wiegel,et al. Guidelines on Prostate Cancer , 2013 .
[20] G. Bubley,et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. , 1998, The Journal of urology.